AZD1152 in patients with Advanced Solid Malignancies
Study identifier:D1531C00002
ClinicalTrials.gov identifier:NCT00338182
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
Medical condition
Tumors
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1152 part A, AZD1152 part B
Sex
All
Actual Enrollment
43
Study type
Interventional
Age
18 Years - 130 Years
Date
Study Start Date: 23 May 2006
Primary Completion Date: 06 Jun 2008
Study Completion Date: 01 Mar 2017
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2017 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD1152 AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment) | Drug: AZD1152 part A 48-hour continuous intravenous infusion Other Name: n/a Drug: AZD1152 part B 2-hour intravenous infusion Other Name: n/a |
Contacts
Investigators
Principal Investigator
Emerging Oncology Medical Science Director
AstraZeneca
